Since strategies acting on the lateral mobility of D1R and glutamate NMDA receptor in the striatum might improve dyskinesia in L-DOPA-treated animal models of the Parkinson disease22, one may envision the surface diffusion of neurotransmitter receptors as a highly valuable therapeutic target. This evidence concerns the gene DRD1 and drug-induced dyskinesia.